Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The goal of the Phase I portion of this study is to find the highest tolerable dose of the
combination of dasatinib and erlotinib hydrochloride that can be given to patients with
advanced solid tumors.
The goal of the Phase II portion of this study is to learn if this combination is effective
when given to patients with non-small cell lung cancer.
The safety of this combination will be studied in both phases.